AbacavirThe nurse practitioner was correct in ordering an HLA-B*5701 allele genetic testing. This ge-netic test is recommended by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and The Food and Drug Administration (FDA) (Dean, 2015). The nurse practitioner was performing one of the most important goals of the pre-administration assessment (Woo & Robinson, 2016). By thoroughly examining the patient's medical history the nurse practitioner was able to identify that this patient is at high risk for the side effects of abacavir. Through phar-macogenomics, we now have an understanding that genetics plays a vital role in the toxicity, up-take, effectiveness, and metabolism of medications (Woo & Robinson, 2016). Patients who do have the gene, HLA-B*5701, are at a higher risk of abacavir-induced hypersensitivity. The nurse practitioner should not prescribe abacavir for this patient. Abacavir is contraindicated for patients who have HLA-B*5701 (Dean, 2015).